Background
HIV drug resistance testing informs regimen design, but some clinical outcomes remain unexplained. Discordance between resistance findings and clinical outcomes challenges interpretation algorithms, especially critical for adolescents and young adults (youth) in resource-limited settings.
Methods
We followed Kenyan youth with perinatal HIV at Academic Model Providing Access to Healthcare (AMPATH) every 6 months for 4 years and characterized resistance and clinical outcomes discordance in two groups: (1) those with resistance to their regimen and subsequent viral load (VL) suppression (VL<200 copies/mL), and (2) those without resistance and subsequent failure (VL>200 copies/mL). Genotyping was attempted for all viremic youth; eligibility required ≥1 genotype consistent with either group. Resistance was defined as Stanford Database level ≥3 to one or more current regimen drug. Associations with discordance were evaluated for age, sex, time on therapy, dolutegravir (DTG)-based regimen, number of drugs with resistance in current regimen, adherence (by a validated questionnaire) and VL, using pooled logistic regression for discrete event-time data, with robust standard errors.
Results
Over 2020-2025, 444 youth were enrolled; 49% female, median 17 years at enrollment, 90% on DTG-based regimens by study end, 53% with HIV-1 subtype A1. Discordances were seen in 29% (128/444) of youth overall, and 79% (128/163) of those with at least one genotype, including 66/71 (93%) in group 1 (27/28-96% on DTG-based regimens; 39/43-91% not on DTG-based regimens), 37% reporting perfect adherence; and 82/111 (74%) in group 2 (66/93-71% on DTG-based regimens; 16/189-89% not on DTG-based regimens), 35% reporting perfect adherence. Group 1 discordance was in 54% by month 6 and 96% by study end, occurring sooner with worse baseline adherence (Odds Ratio (OR=1.6 per 1 higher non-adherence, Confidence Interval (CI): 1.0-2.5, p=0.048) and lower VL (OR=0.5 per 1-log higher VL, CI: 0.2-1.1, p=0.10). Group 2 discordance was in 48% by month 6 and 88% by study end, occurring sooner with higher baseline VL (OR=1.4 per 1-log higher VL, CI: 1.1-1.7, =0.01).
Conclusions
Discordance between HIV drug resistance and clinical outcomes is common in Kenyan youth, highlighting limitations to current interpretation algorithms, suggesting mechanisms beyond conventional resistance and adherence, and underscoring the need for further research to guide care in the DTG era.